Workflow
对话微芯生物鲁先平:中国创新药技术壁垒高甚至超过半导体和新能源

Group 1 - The 21st Summer Annual Meeting of the Yabuli Entrepreneur Forum took place in Guangzhou on September 12-13, 2025, focusing on the theme "Forging Ahead Steadily - Corporate Development in the New Global Context" [1] - The chairman and general manager of Microchip Biotech, Lu Xianping, stated that Chinese biopharmaceutical companies have established high-level technological barriers, which he considers to be among the best in the domestic industry [1] - The innovative drug industry has seen significant market capitalization growth this year, with some leading companies doubling their market value, indicating a rising recognition of Chinese innovative drug companies' R&D capabilities globally [1] Group 2 - Despite the optimistic outlook, Lu Xianping acknowledged that the industry faces challenges, particularly the need for reasonable profit support to drive innovation as companies approach the critical 0 to 1 stage [1] - The core issue for future industry development is to overcome key technologies, including AI computing power, special algorithms, big data modeling capabilities, and original research [1]